Drug shortages in Israel, revisited: a bitter pill to swallow

Author:

Schwartzberg EyalORCID,Marom Eli,Vishkautzan Alla,Gorelik Einat,Shani Segev

Abstract

Abstract Background In 2017, we published an article addressing drug shortages (DS) in Israel, exploring regulatory perspectives, challenges, and potential solutions. Since then, DS remain a significant concern for patients, healthcare providers, and policymakers globally. In this updated article, we revisit the topic, providing new insights, data, and analysis on the current DS landscape in Israel, efforts to mitigate them, and propose strategies to combat this escalating issue. Methods We conducted a comprehensive search of the Israeli Ministry of Health (MOH) DS database, spanning from 2014 to the present. We extracted DS numbers and their reasons. Further searches on the Israeli MOH website, pharmaceutical division archives, and the internet yielded official MOH publications and correspondence regarding regulatory responses to DS from 2017 onwards. Additionally, two specific cases of DS were examined to analyze their handling. Recent activities and publications from the Israeli MOH aimed at reducing DS were also reviewed. Results Between 2014 and 2022, DS surged 2.66-fold. Total DS were 3228; 672 due to commercial reasons, and 2556 to operational reasons (20.5% and 79.5% respectively). The average duration of intermittent DS increased 1.56-fold, from 85 to 133 days. Manufacturers informed the MOH 22 days prior to actual shortage on average. Analyzing 2022's DS (640) by ATC groups, prominent categories included nervous system drugs (18%), drugs acting on the alimentary tract and metabolism (14%), and dermatologicals (11%). Operational DS in 2022 (n = 564) were primarily due to stock delivery delays (38%), stock over-utilization (12%), and raw material shortages (9%). Sixteen official MOH publications on DS were identified from 2017 onwards. Moreover, two high-impact DS case studies were examined. Conclusion Despite routine monitoring by the Israeli MOH and updating the DS policy throughout this period, DS persist, intensifying annually and posing serious health risks. This trend mirrors international patterns, affecting countries globally. In Israel's uniquely structured healthcare system, with its swift stakeholder cooperation and implementation capabilities, more effective DS management is conceivable. We propose ten universally applicable rules to address DS challenges.

Publisher

Springer Science and Business Media LLC

Reference30 articles.

1. European Commission, Directorate-General for Health and Food Safety, Jongh T, Becker D, Mathieu B. Future-proofing pharmaceutical legislation: study on medicine shortages: final report (revised). Publ Off Eur Union. 2021.

2. Vogler S, Fischer S. How to address medicines shortages: findings from a cross-sectional study of 24 countries. Health Policy (New York). 2020;124(12):1287–96.

3. Miljković N, Godman B, Kovačević M, et al. Prospective risk assessment of medicine shortages in Europe and Israel: findings and implications. Front Pharmacol. 2020;11(March):1–14.

4. Chapman S, Dedet G, Lopert R. Shortages of medicines in OECD countries. OECD Health Work Pap. 2022;(137):1–54. https://www.oecd-ilibrary.org/docserver/b5d9e15d-en.pdf?expires=1659005079&id=id&accname=guest&checksum=3BDA5DF91510605DFDA878BA1B56D1E5. Accessed 28 Oct 2023.

5. Papers W. Suppl-Mat-1-OECD-analysis-of-national-shortage-monitoring-systems-2022. 2022;(January 2021):1–22.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3